These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

223 related items for PubMed ID: 16827720

  • 1. Mechanisms involved in the enhancement of osteoclast formation by enamel matrix derivative.
    Itoh N, Kasai H, Ariyoshi W, Harada E, Yokota M, Nishihara T.
    J Periodontal Res; 2006 Aug; 41(4):273-9. PubMed ID: 16827720
    [Abstract] [Full Text] [Related]

  • 2. Enamel matrix derivative promotes osteoclast cell formation by RANKL production in mouse marrow cultures.
    Otsuka T, Kasai H, Yamaguchi K, Nishihara T.
    J Dent; 2005 Oct; 33(9):749-55. PubMed ID: 16199283
    [Abstract] [Full Text] [Related]

  • 3. [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro].
    Xiao XH, Zhou HD, Yuan LQ, Xie H, Liao EY.
    Zhonghua Yi Xue Za Zhi; 2004 Dec 17; 84(24):2102-6. PubMed ID: 15730627
    [Abstract] [Full Text] [Related]

  • 4. RANKL-stimulated osteoclast-like cell formation in vitro is partially dependent on endogenous interleukin-1 production.
    Lee SK, Gardner AE, Kalinowski JF, Jastrzebski SL, Lorenzo JA.
    Bone; 2006 May 17; 38(5):678-85. PubMed ID: 16309985
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Furosin, an ellagitannin, suppresses RANKL-induced osteoclast differentiation and function through inhibition of MAP kinase activation and actin ring formation.
    Park EK, Kim MS, Lee SH, Kim KH, Park JY, Kim TH, Lee IS, Woo JT, Jung JC, Shin HI, Choi JY, Kim SY.
    Biochem Biophys Res Commun; 2004 Dec 24; 325(4):1472-80. PubMed ID: 15555594
    [Abstract] [Full Text] [Related]

  • 7. c-myc is required for osteoclast differentiation.
    Battaglino R, Kim D, Fu J, Vaage B, Fu XY, Stashenko P.
    J Bone Miner Res; 2002 May 24; 17(5):763-73. PubMed ID: 12009006
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 1'-Acetoxychavicol acetate inhibits RANKL-induced osteoclastic differentiation of RAW 264.7 monocytic cells by suppressing nuclear factor-kappaB activation.
    Ichikawa H, Murakami A, Aggarwal BB.
    Mol Cancer Res; 2006 Apr 24; 4(4):275-81. PubMed ID: 16603641
    [Abstract] [Full Text] [Related]

  • 11. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NF kappa B ligand (RANKL) or tumor necrosis factor-alpha (TNF-alpha).
    Woo JT, Nakagawa H, Krecic AM, Nagai K, Hamilton AD, Sebti SM, Stern PH.
    Biochem Pharmacol; 2005 Jan 01; 69(1):87-95. PubMed ID: 15588717
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Inhibition of osteoclast differentiation by polycyclic aryl hydrocarbons is dependent on cell density and RANKL concentration.
    Voronov I, Heersche JN, Casper RF, Tenenbaum HC, Manolson MF.
    Biochem Pharmacol; 2005 Jul 15; 70(2):300-7. PubMed ID: 15919055
    [Abstract] [Full Text] [Related]

  • 15. Mitogen-activated protein kinases mediate interleukin-1beta-induced receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells.
    Oikawa A, Kobayashi M, Okamatsu Y, Shinki T, Kamijo R, Yamamoto M, Hasegawa K.
    J Periodontal Res; 2007 Aug 15; 42(4):367-76. PubMed ID: 17559635
    [Abstract] [Full Text] [Related]

  • 16. Osteoprotegerin and receptor activator of nuclear factor-kappa B ligand modulation by enamel matrix derivative in human alveolar osteoblasts.
    Galli C, Macaluso GM, Guizzardi S, Vescovini R, Passeri M, Passeri G.
    J Periodontol; 2006 Jul 15; 77(7):1223-8. PubMed ID: 16805686
    [Abstract] [Full Text] [Related]

  • 17. A novel PPARgamma agonist, KR62776, suppresses RANKL-induced osteoclast differentiation and activity by inhibiting MAP kinase pathways.
    Park JY, Bae MA, Cheon HG, Kim SS, Hong JM, Kim TH, Choi JY, Kim SH, Lim J, Choi CH, Shin HI, Kim SY, Park EK.
    Biochem Biophys Res Commun; 2009 Jan 16; 378(3):645-9. PubMed ID: 19059209
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways.
    Takami M, Cho ES, Lee SY, Kamijo R, Yim M.
    FEBS Lett; 2005 Jan 31; 579(3):832-8. PubMed ID: 15670856
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.